Codice QR

Potential Immune Microenvironment Biomarkers in SCLC: J-TAIL-2 Observational Study

Introduction: Effective predictors of response to atezolizumab plus carboplatin/etoposide (CE) therapy in extensive-stage SCLC (ES-SCLC) remain limited. This exploratory analysis from J-TAIL-2 aimed to identify markers of survival benefit with atezolizumab plus CE therapy in ES-SCLC. Methods: J-TAIL...

Descrizione completa

Salvato in:
Autori principali: Masayuki Shirasawa, MD, PhD, Makoto Nishio, MD, PhD, Kadoaki Ohashi, MD, PhD, Atsushi Osoegawa, MD, PhD, Eiki Kikuchi, MD, PhD, Hideharu Kimura, MD, PhD, Yasushi Goto, MD, PhD, Junichi Shimizu, MD, PhD, Eisaku Miyauchi, MD, PhD, Hiroshige Yoshioka, MD, PhD, Ichiro Yoshino, MD, PhD, Toshihiro Misumi, PhD, Yasushi Yatabe, MD, PhD, Tatsuya Yoshida, MD, PhD, Jumpei Kashima, MD, PhD, Masahide Oki, MD, PhD, Hisao Ashimura, MS, Yuki Kobayashi, MS, Misa Tanaka, MS, Akihiko Gemma, MD, PhD
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2026-03-01
Serie:JTO Clinical and Research Reports
Soggetti:
Small cell
Lung cancer
Atezolizumab
Chemotherapy
Immune microenvironment
Accesso online:http://www.sciencedirect.com/science/article/pii/S2666364325001444
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi